东吴证券首予皓元医药买入评级，2021年中报点评：业绩符合我们预期，前后端业务双轮驱动的小分子合成专家

七印授权

5P7FUZ6JEZIM4O71A95O4KAQJ50C469V600TL7M9YU0ZBI2SD5

2021-08-27 00:17:36

article

00AB4E20B39EB07E118DE4C9DA61A54208D2C64E68B04AE11368F2CBB84EF7B2

zh-CN

C1544443810DE1F5A1709DFBC751FAD783CF99AA

10593956

02636d79fc7c7cc37b9cb348037eec28743d030e5d570d0d69837a3587bed31880

6ae80da3f3fda10dd1b6a9873c94d2bd49e45f7a79caf4084ac35d52818bc1217d6c77a122b4d20d91c366100af7da963b08b453560645eb5764c721389d60411b

{"parameters":{"adaptation":"n","price":"100000"},"type":"cm"}

yuanben_61282f207aaa67.36398585

原本认证

https://www.yuanben.io/article/774a32d1-73d6-4961-b86c-c2fb1cd86e29

{"author":"每日经济新闻","authorization_pub_key":"03040cbbeae1adf91c3efd7306d09c6005403a041f9b7405dac489d4f8126fef8c"}